NEWS

Adoption of Liquid Biopsy Tests for NSCLC

“Availability of biomarker data early in the treatment process enables tumor boards to review cases more efficiently and to better understand treatment options.”

The Future Is Fluid

“Liquid biopsy really opens the possibility of a kind of real-time molecular analysis of the tumor to help inform treatment choices,” Dr. Burstein concluded.

Tests Demonstrate Ability to Stratify Patients Treated with Immunotherapy

“VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist in the division of medical oncology at the University of Ottawa. Biodesix presented data relating to immunotherapy selection, afatinib efficacy.

VIEW OUR BLOGS

READ

HOME     CONTACT     TERMS & CONDITIONS     CAREERS     FAQ     SITE MAP     NEWS

ORDER A TEST KIT

CLICK HERE